Основная статистика
| LEI | 969500667RSYIH8YL895 |
| CIK | 1760854 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nanobiotix S.A. - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 2, 2025 |
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference EXHIBIT 99.1 Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, an |
|
| August 27, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) In |
|
| July 11, 2025 |
EXHIBIT 99.1 NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major markets Medicinal product classification supports unified global regu |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 July 2nd, 2025 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 INFORMATION CONT |
|
| July 2, 2025 |
2025DD1045711 FR0011341205 - DD188343 02 juillet 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| June 10, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 10, 2025 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 28, 2025 |
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference EXHIBIT 99.1 NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced tod |
|
| May 27, 2025 |
2025DD1039917 FR0011341205 - DD187700 27 mai 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 INFOR |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 INFOR |
|
| May 27, 2025 |
2025DD1039719 FR0011341205 - DD187665 26 mai 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 21, 2025 |
Nanobiotix Provides First Quarter 2025 Operational and Financial Update EXHIBIT 99.1 Nanobiotix Provides First Quarter 2025 Operational and Financial Update Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancer Presentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC a |
|
| May 15, 2025 |
exhibit991may152025 2025DD1038006 FR0011341205 - DD187429 15 mai 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2025 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 INFOR |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 14, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuter |
|
| May 14, 2025 |
As filed with the Securities and Exchange Commission on May 14, 2025 As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. |
|
| May 14, 2025 |
Exhibit 99.1 NANOBIOTIX 2023 STOCK OPTION PLAN Nanobiotix – Stock-option Grant Agreement SUMMARY Page 1. PURPOSES OF THE PLAN 1 2. DEFINITIONS 1 3. SHARES SUBJECT TO THE PLAN 4 4. ADMINISTRATION OF THE PLAN 5 (a) Procedure 5 (b) Powers of the Administrator 5 (c) Effect of Administrator’s Decision 6 5. LIMITATIONS 6 6. TERM OF PLAN 7 7. TERM OF OPTIONS 7 8. OPTIONS EXERCISE PRICE AND CONSIDERATION |
|
| May 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Nanobiotix S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2)(3) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Ordinary shares, €0. |
|
| May 14, 2025 |
Exhibit 99.2 NANOBIOTIX 2025 STOCK OPTION PLAN Nanobiotix – Stock-option Plan SUMMARY Page 1. PURPOSES OF THE PLAN 1 2. DEFINITIONS 1 3. SHARES SUBJECT TO THE PLAN 4 4. ADMINISTRATION OF THE PLAN 5 (a) Procedure 5 (b) Powers of the Administrator 5 (c) Effect of Administrator’s Decision 6 5. LIMITATIONS 6 6. TERM OF PLAN 7 7. TERM OF OPTIONS 7 8. OPTIONS EXERCISE PRICE AND CONSIDERATION 7 (a) Subsc |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 12, 2025 |
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ EXHIBIT 99.1 Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major dis |
|
| May 5, 2025 |
EXHIBIT 99.1 Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached] |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| April 30, 2025 |
EXHIBIT 99.1 Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic ca |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 14, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 14, 2025 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reut |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 14, 2025 |
2025DD1031953 FR0011341205 - DD187019 14 avril 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| April 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 |
|
| April 10, 2025 |
2025DD1031083 FR0011341205 - DD186943 09 avril 2025 INFORMATION Déclaration individuelle relative aux opérations des personnes mentionnées à l’article L. |
|
| April 2, 2025 |
Exhibit 4.6.1 CONFIDENTIAL Execution Version Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Janssen Pharmaceutica NV 30 Turnhoutseweg B-2340 Beerse, Belgium March 14 |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 2, 2025 |
TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of October, 2024 (the “Effective Date”), is entered into by and between Janssen Pharmaceutica NV, a limited liability company organized under the laws of Belgium (“JPNV”) and Nanobiotix S. |
|
| April 2, 2025 |
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancer Disciplined financial strategy toward long-term sustainability and growth continues to strengthe |
|
| April 2, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bart Van Rhij |
|
| April 2, 2025 |
Translation for information purposes only NANOBIOTIX A French societe anonyme with executive board and supervisory board with a capital of 1,413,999. |
|
| April 2, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurent Levy, |
|
| April 2, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Laurent Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 2, 2025 |
NANOBIOTIX S.A. INSIDER TRADING POLICY Exhibit 11.1 NANOBIOTIX S.A. INSIDER TRADING POLICY This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of Nanobiotix S.A. (the “Company”) or any related financial instrument (collectively, the “Company Securities”) and the handling of confidential information about the Company and the companies with which the Company does business. As set |
|
| April 2, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement No. 333-285604 on Form F-3 and Nos. 333-253062, 333-257239, 333-272947 on Form S-8 of our report dated April 2 2025, with respect to the consolidated financial statements of Nanobiotix S.A. /s/ KPMG S.A. /s/ Cédric Adens Partner Paris-La Défense, France A |
|
| April 2, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bart Van Rhijn, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A.(the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mat |
|
| April 2, 2025 |
EXECUTION VERSION CONFIDENTIAL 1 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is entered into this day of October, 2024, by and between Nanobiotix S. |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 2, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1.Registration Statement (Form S-8 No. 333-253062) pertaining to the historical BSA Plans (04-12, 2013, 2014, 2015-1, 2015-2(a), 2016 Ordinary, 2016 Performance, 2016-02, 2017, 2018, 2018-01, 2018-02, 2019-1, 2020), historical BSPCE Plans (201 |
|
| March 31, 2025 |
EXHIBIT 99.1 NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nan |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 27, 2025 |
EXHIBIT 99.1 Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed A preliminary review of survival d |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 20, 2025 |
EXHIBIT 99.1 NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be pres |
|
| March 17, 2025 |
EXHIBIT 99.1 NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinic |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 13, 2025 |
Nanobiotix S.A. 60, rue de Wattignies 75012 Paris, France March 13, 2025 Nanobiotix S.A. 60, rue de Wattignies 75012 Paris, France March 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell RE: Nanobiotix S.A. Registration Statement on Form F-3 (File No. 333-285604) Dear Mr. Campbell: In accordance with Rules 460 and 461 under the Se |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 13, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, March 13, 2025 (GLOBE NEWSWIRE) - Paris, France, March 13, 2025 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq |
|
| March 6, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Registration Statement Form F-3 (Form Type) Nanobiotix S. |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
Exhibit 4.1 Translation for information purposes only NANOBIOTIX A French societe anonyme with executive board and supervisory board with a capital of 1,413,999.84 euros Registered office: 60, rue de Wattignies, 75012 Paris Paris Trade and Companies Registry no. 447 521 600 BYLAWS Updated as of May 28, 2024 True copy certified by the chairman of the executive board 1 TITLE I FORM, NAME. PURPOSE, H |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| February 12, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 12, 2025 (GLOBE NEWSWIRE) - Paris, France, February 12, 2025 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasd |
|
| January 29, 2025 |
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 EXHIBIT 99.1 Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025 PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announc |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| January 21, 2025 |
EXHIBIT 99.1 NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approac |
|
| January 10, 2025 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE) - Paris, France, January 9, 2025 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| December 17, 2024 |
EXHIBIT 99.1 NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024 Participants can register here for the virtual event airing 9:00am ET / 3:00pm CET PARIS and CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pione |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2024 Commission File Number: 001-39777 NANOBIOTIX S.A. (Translation of registrant’s name into English) 60 rue de Wattignies 75012 Paris, France (Address of principal executive offices) 1 |
|
| December 11, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE) - Paris, France, December 11, 2024 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasd |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 9, 2024 |
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer EXHIBIT 99.1 NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial 23 months median Overall Survival from date of diagnosis was observed in 22 patients with locally advanced or borderline resectable pancreatic |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 13, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE) - Paris, France, November 13, 2024 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasd |
|
| November 12, 2024 |
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms EXHIBIT 99.1 NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms Transferred US sponsorship of global Phase 3 NANORAY-312 head and neck cancer study, a key step in the preparation for potential NBTXR3 regulatory submission Added expert industry leaders to Supervisory Board, further strengthening support for the Company’s long-term growth strategy NBTXR3 program |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| October 31, 2024 |
EXHIBIT 99.1 NANOBIOTIX to Participate in Multiple Investor Conferences in November ~ Guggenheim’s Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage b |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| October 11, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2024 (GLOBE NEWSWIRE) - Paris, France, October 11, 2024 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasda |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 18, 2024 Commission File Number: 001-39777 NANOBIOTIX S.A. (Exact name of registrant as specified in its charter) Nanobiotix S.A. 60 rue de Wattignies 75012 Paris, France (Address of p |
|
| September 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 18, 2024 |
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results RT-NBTXR3 followed by anti-PD-1 demonstrated favorable safety profile, disease control and tumor response in patients both naïve and resistant to anti-PD-1, suggesting that NBTXR3 may prime the immune system before checkpoint therapy Several clinical milestones expected over the next 12-18 months includin |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 4, 2024 |
EXHIBIT 99.1 NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth Dr. Margaret A. Liu, global expert in vaccines, gene therapy, and cancer immunotherapy; chief executive officer of PAX Therapeutics and member of several boards Ms. Anat Naschitz, proven life science investor and entrepreneur; co-founder of OrbiMed Israel PAR |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 3, 2024 |
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference EXHIBIT 99.1 Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management |
|
| August 8, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 08, 2024 (GLOBE NEWSWIRE) - Paris, France, August 8, 2024 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) In |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| July 9, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, July 09, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| June 12, 2024 |
EXHIBIT 99.1 NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities f |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| June 11, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 11, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| June 3, 2024 |
EXHIBIT 99.1 Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-P |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 28, 2024 |
EXHIBIT 99.1 NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or meta |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 23, 2024 |
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference EXHIBIT 99.1 NANOBIOTIX to Present at the Jefferies Global Healthcare Conference PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate |
|
| May 22, 2024 |
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update EXHIBIT 99.1 NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and |
|
| May 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 21, 2024 |
EXHIBIT 99.1 Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth Updated Nanobiotix corporate strategy designed to enable long-term growth through execution of the global NBTXR3 collaboration and platforms beyond NBTXR3 Alignment of intent to transfer the sponsorship of the ongoing Phase 3 pivotal trial in head and n |
|
| May 16, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 16, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuter |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 15, 2024 |
EXHIBIT 99.1 NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand trea |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 14, 2024 |
EXHIBIT 99.1 NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possib |
|
| April 24, 2024 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurent Levy, |
|
| April 24, 2024 |
EUI-1217246584v3 DATED 18 APRIL 2024 Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 EUROPEAN INVESTMENT BANK (the Bank) - and - NANOBIOTIX (the Company) AMENDMENT AGREEMENT N°2 RELATING TO A ROYALTY AGREEMENT DATED 26 JULY 2018 AS AMENDED BY AN AMENDMENT AGREEMENT DATED 18 OCTOBER 2022 EUI-1217246584v3 2 CONTENTS CLAUSE PAGE 1. |
|
| April 24, 2024 |
Securities and Exchange Commission Exhibit 15.2 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen, We have read Item 16F. Change in Registrant’s Certifying Accountant on pages 163 of Form 20-F dated April 24, 2024, of Nanobiotix S.A. and are in agreement with the statements contained in paragraphs one, four, and six. Regarding the registrant's statement concerning a material weakness in |
|
| April 24, 2024 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bart Van Rhij |
|
| April 24, 2024 |
exhibit451-assignmentagr NOVATION AGREEMENT This NOVATION AGREEMENT (this “Agreement”) is made as of December 22, 2023, (the “Effective Date”), by and among LianBio Development (HK) Limited (as successor-in-interest to Lian Oncology Limited) (“Lian”), LianBio (“Lian Cayman”), Janssen Pharmaceutica NV (“Assignee”), and Nanobiotix S. |
|
| April 24, 2024 |
NANOBIOTIX SA COMPENSATION RECOVERY POLICY (Adopted and approved on September 21, 2023) Exhibit 97 NANOBIOTIX SA COMPENSATION RECOVERY POLICY (Adopted and approved on September 21, 2023) 1. |
|
| April 24, 2024 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| April 24, 2024 |
NANOBIOTIX 2023 STOCK OPTION PLAN Exhibit 4.22 NANOBIOTIX 2023 STOCK OPTION PLAN Nanobiotix – Stock-option Grant Agreement SUMMARY Page Exhibit – Stock Option Grant Agreement Part I – Notice of Stock option grant Part II – Terms and conditions Exercise notice -i- EUI-1215975066v1 NANOBIOTIX 2023 STOCK OPTION PLAN 1.Purposes of the Plan According to the authorization granted pursuant to the thirty-first resolution of the combined s |
|
| April 24, 2024 |
exhibit25-omnibusrestric |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 24, 2024 |
exhibit24-registrationri Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 11, 2023 by and among Nanobiotix S. |
|
| April 24, 2024 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Laurent Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 24, 2024 |
exhibit422-beixnanobioti EUI-1217244467v4 Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 NANOBIOTIX EGFF Amendment Agreement n°2 in relation to the Finance Contract signed on 26 July 2018, as amended by an amendment agreement dated 18 October 2022 between the EUROPEAN INVESTMENT BANK and NANOBIOTIX 18 April 2024 EUI-1217244467v4 2 CONTENTS 1. |
|
| April 24, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: 1.Registration Statement (Form S-8 No. 333-253062) pertaining to the historical BSA Plans (04-12, 2013, 2014, 2015-1, 2015-2(a), 2016 Ordinary, 2016 Performance, 2016-02, 2017, 2018, 2018-01, 2018-02, 2019-1, 2020), historical BSPCE Plans (201 |
|
| April 24, 2024 |
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety p |
|
| April 24, 2024 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bart Van Rhijn, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A.(the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mat |
|
| April 17, 2024 |
EXHIBIT 99.1 NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024 Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST PARIS and CAMBRIDGE, Mass., April 17, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 10, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, April 10, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reut |
|
| April 2, 2024 |
EXHIBIT 99.1 Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer (“NSCLC”) who have previously received definitive radiation therapy |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| March 6, 2024 |
Nanobiotix to Present at Upcoming Investor Conferences in March EXHIBIT 99.1 Nanobiotix to Present at Upcoming Investor Conferences in March PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate i |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| February 13, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Feb. 13, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| February 9, 2024 |
FR:NANO / Nanobiotix S.A. / Artal International S.C.A. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 3) NANOBIOTIX S.A. (Name of Issuer) Ordinary Shares, €0.03 nominal value per share (Title of Class of Securities) 63009J107** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 8, 2024 |
EX-99.(A) 2 ex99-a.htm ITEM 7 INFORMATION Qatar Investment Authority CUSIP 63009J107 SC 13G Page 7 of 8 EXHIBIT A The Schedule 13G to which this attachment is appended is filed by Qatar Investment Authority on behalf of itself and the following subsidiaries: QH Oil Investments LLC |
|
| February 8, 2024 |
EX-99.(B) 3 ex99-b.htm CERTIFICATE OF INCUMBENCY Qatar Investment Authority CUSIP 63009J107 SC 13G Page 8 of 8 EXHIBIT B CERTIFICATE OF INCUMBENCY I, Ahmad Mohammed F Q Al-Khanji, Chief of Legal and General Counsel, of Qatar Investment Authority, established by Emiri Decision No 22 in 2005, with its registered office at, Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61) |
|
| February 8, 2024 |
FR:NANO / Nanobiotix S.A. / Qatar Investment Authority - AMENDMENT TO SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nanobiotix S.A. (Name of Issuer) Ordinary shares, nominal value €0.03 per share (Title of Class of Securities) 63009J107** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the ru |
|
| February 2, 2024 |
FR:NANO / Nanobiotix S.A. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment SC 13G/A 1 s13ga011924-nanobiotix.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Nanobiotix S.A. (Name of Issuer) Ordinary Shares, €0.03 nominal value per share (Title of Class of Se |
|
| January 31, 2024 |
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference EXHIBIT 99.1 Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder o |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| January 29, 2024 |
EXHIBIT 99.1 Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients wit |
|
| January 12, 2024 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 11, 2024 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| January 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 26, 2023 |
EXHIBIT 99.1 Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets PARIS and CAMBRIDGE, Mass., Dec. 26, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 13, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 13, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| December 4, 2023 |
EXHIBIT 99.1 Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc. Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, M |
|
| November 16, 2023 |
EX-99.A 2 d568772dex99a.htm EX-99.A Exhibit 99.A CUSIP No. 63009J107 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit A, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Dated: Novembe |
|
| November 16, 2023 |
FR:NANO / Nanobiotix SA / Johnson & Johnson Innovation - JJDC, Inc. - SC 13G Passive Investment SC 13G CUSIP No. 63009J107 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Nanobiotix S.A. (Name of Issuer) Ordinary Shares, €0.03 nominal value per share (Title of Class of Securities) 63009J107* (CUSIP |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 13, 2023 |
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update EXHIBIT 99.1 NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update $2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated (RT) NBTXR3 in topline Study 102 Phase 1 data i |
|
| November 9, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 08, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 9, 2023 |
EXHIBIT 99.1 NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023 Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET PARIS and CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 8, 2023 |
NANOBIOTIX Announces Closing of Global Offering EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 NANOBIOTIX Announces Closing of Global Offering PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the closing today |
|
| November 8, 2023 |
EX-99.A 2 ex-a.htm ITEM 7 INFORMATION Qatar Investment Authority SC13G CUSIP No. 63009J107 EXHIBIT A The Schedule 13G to which this attachment is appended is filed by Qatar Investment Authority on behalf of itself and the following subsidiaries: QH Oil Investments LLC |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nanobiotix S.A. (Name of Issuer) Ordinary shares, nominal value €0.03 per share (Title of Class of Securities) 63009J107** (CUSIP Number) November 2, 2023 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the rule |
|
| November 8, 2023 |
EX-99.B 3 ex-b.htm CERTIFICATE OF INCUMBENCY Qatar Investment Authority SC13G CUSIP No. 63009J107 EXHIBIT B CERTIFICATE OF INCUMBENCY I, Ahmad Mohammed F Q Al-Khanji, Chief of Legal and General Counsel, of Qatar Investment Authority, established by Emiri Decision No 22 in 2005, with its registered office at, Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 7, 2023 |
Exhibit 1.1 NANOBIOTIX S.A. (a société anonyme incorporated under the laws of France) 2,492,223 Ordinary Shares and 3,106,907 American Depositary Shares, Each Representing One (1) Ordinary Share (Nominal Value €0.03 Per Share) UNDERWRITING AGREEMENT November 2, 2023 JEFFERIES LLC LEERINK PARTNERS LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Ma |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 Date of Report: November 7, 2023 Commission File Number: 001-39777 NANOBIOTIX S.A. (Exact Name of Registrant as Specified in its Charter) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive of |
|
| November 6, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-262545 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 16, 2022) 5,599,130 Ordinary Shares (Including 3,106,907 Ordinary Shares In the Form of American Depositary Shares) We are offering 5,599,130 ordinary shares, €0.03 nominal value per share, in a global offering consisting of (i) a public offering in the United States |
|
| November 6, 2023 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $30,000,000. |
|
| November 2, 2023 |
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus Dated November 2, 2023 Registration Statement No. |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 2, 2023 |
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M EXHIBIT 99.1 NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing |
|
| November 2, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilit |
|
| November 2, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-262545 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any jurisdiction where the offer or the sale is not permitt |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| November 2, 2023 |
Filed Pursuant to Rule 433 of the Securities Act of 1933 Issuer Free Writing Prospectus Dated November 1, 2023 Registration Statement No. |
|
| October 23, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023 Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and reco |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| October 11, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 11, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| October 4, 2023 |
EXHIBIT 99.1 Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) I |
|
| September 29, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST PARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 28, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a tolerable safety p |
|
| September 26, 2023 |
Summary of Janssen Agreement and the JJDC SPA Exhibit 99.2 Summary of Janssen Agreement and the JJDC SPA As discussed in the Company’s Half-Year Financial Report From January 1, 2023 to June 30, 2023, which is included as Exhibit 99.1 to the Company’s Report on Form 6-K furnished to the SEC on September 26, 2023, the following summary sets forth the material terms of the Janssen Agreement and the JJDC SPA (each as defined therein). Partnershi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 26, 2023 Commission File Number: 001-39777 NANOBIOTIX S.A. (Exact name of registrant as specified in its charter) Nanobiotix S.A. 60 rue de Wattignies 75012 Paris, France (Address of p |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 26, 2023 |
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023 EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023 Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends cash runway into the fi |
|
| September 26, 2023 |
Additional Risk Factor relating to Janssen Agreement Exhibit 99.3 Additional Risk Factor relating to Janssen Agreement As discussed in the Company’s Half-Year Financial Report From January 1, 2023 to June 30, 2023, which is included as Exhibit 99.1 to the Company’s Report on Form 6-K furnished to the SEC on September 26, 2023, in light of the Company’s entry into the Janssen Agreement (as defined therein), the Company is providing the following supp |
|
| September 19, 2023 |
EXHIBIT 99.1 Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand tre |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 13, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 13, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reut |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| September 5, 2023 |
EXHIBIT 99.1 NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities fo |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) |
|
| August 31, 2023 |
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference EXHIBIT 99.1 NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) In |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) In |
|
| August 15, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3 PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to ex |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) In |
|
| August 4, 2023 |
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023 EXHIBIT 99.1 NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023 PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company wi |
|
| July 20, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, July 20, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| July 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| July 19, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers PARIS and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibil |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| July 10, 2023 |
EXHIBIT 99.1 NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3 PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patien |
|
| June 27, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Nanobiotix S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, €0.03 nomina |
|
| June 27, 2023 |
Summary of 2023 Free Share (AGA) Plan Exhibit 99.1 Summary of 2023 Free Share (AGA) Plan Free shares, or AGA (actions gratuites), may be granted by our executive board to our employees, employees of our subsidiaries and members of our executive board. Administration. Pursuant to delegations granted at our general meeting of the shareholders, our executive board, upon recommendation of the compensation committee and with the approval o |
|
| June 27, 2023 |
As filed with the Securities and Exchange Commission on June 27, 2023 As filed with the Securities and Exchange Commission on June 27, 2023 Registration No. |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indi |
|
| June 8, 2023 |
EXHIBIT 99.1 Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, June 08, 2023 (GLOBE NEWSWIRE) - Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reute |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 17, 2023 |
EXHIBIT 99.1 NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update Reported €30.2 million in cash and cash equivalents as of March 31, 2023 PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for p |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Indic |
|
| May 5, 2023 |
EXHIBIT 99.1 NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company Company agreed to term sheet as of May 3, 2023 PARIS and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), today announced that the Company |
|
| April 25, 2023 |
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results EXHIBIT 99.1 NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results Pivotal Phase 3 trial NANORAY-312 ongoing globally with 104 sites activated in 25 countries to date; interim efficacy analysis after 67% of planned progression free survival (PFS) events expected in H2 2024, as planned Final data from Study 102 in head and neck cancer expected in H2 2023 First pancreatic |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 24, 2023 |
Exhibit 4.2.1 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: 2018-0245 NANOBIOTIX |
|
| April 24, 2023 |
Exhibit 4.6 Summary of HSBC France Loan On June 22, 2020, the Company entered into a State-guaranteed loan agreement (prêt garanti par l’Etat) with HSBC France (“HSBC”) to be applied to the Company’s general business needs (the “HSBC PGE Loan”). The €5 million loan is 90% guaranteed by the French State. The loan had an initial maturity of 12 months and an interest rate of 0.00% for this initial 12 |
|
| April 24, 2023 |
Exhibit 4.21 18 October 2022 Contract number (FI No.): 89427 Contract number (FI No.): 89987 Serapis No.: 2018-0245 Nanobiotix (EGFF) European Investment Bank (as Beneficiary) - and – Nanobiotix Corp. (as Guarantor) Autonomous First Demand Guarantee (Garantie Autonome à Première Demande) \\1076678 4131-7639-8908 v3 Hogan Lovells Contents Clause Page 1. Definitions and Interpretation 1 2. The Guara |
|
| April 24, 2023 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Bart Van Rhijn, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A.(the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mat |
|
| April 24, 2023 |
Description of Securities registered under Section 12 of the Exchange Act Exhibit 2.3 Exhibit 2.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2022, Nanobiotix S.A. (the “Company,” “we,” “us,” and “our”) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of each exchange on which registered American depositary shares, each representing on |
|
| April 24, 2023 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bart Van Rhij |
|
| April 24, 2023 |
Exhibit 4.4.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDMENT NO. 1 TO AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT This Amendment No. 1 (“Amendment”) is entered into as of June 4, 2021 (“Amendment No. 1 Effective Date”) by and b |
|
| April 24, 2023 |
Consent of Ernst & Young et Autres Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1)Registration Statement (Form S-8 No. |
|
| April 24, 2023 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of Nanobiotix S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Laurent Levy, |
|
| April 24, 2023 |
) of the registrant (English translation) Translation for information purposes only NANOBIOTIX A French société anonyme with executive board and supervisory board with a capital of 1,046,276. |
|
| April 24, 2023 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Laurent Levy, certify that: 1. I have reviewed this annual report on Form 20-F of Nanobiotix S.A. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a mate |
|
| April 24, 2023 |
EX-4.7 8 a2022xex47xsummaryofbpifra.htm EX-4.7 Exhibit 4.7 Summary of Bpifrance Loan On July 10, 2020, the Company entered into a State-guaranteed loan agreement (prêt garanti par l’Etat) with Bpifrance Financement to be applied to the Company’s cash flow needs. The €5 million loan has a six-year term and is 90% guaranteed by the French State. The loan bore no interest for the first 12 month perio |
|
| April 24, 2023 |
Exhibit 4.3.1 CERTAIN CONFIDENTIAL PORTIONS HAVE BEEN REDACTED FROM THIS EXHIBIT BECAUSE THEY ARE BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN IDENTIFIED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. Dated 18 October 2022 Contract number (FI No): 89427 Contract number (FI No): 89987 Serapis No: |
|
| April 17, 2023 |
EXHIBIT 99.1 NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023 Conference Call and Webcast to be Held at 2:00 PM CEST/8:00 AM EDT on April 25, 2023 PARIS and CAMBRIDGE, Mass., April 17, 2023 (GLOBE NEWSWIRE) - NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-stage clinical biotechnology company pioneering physics-based approac |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39777 Nanobiotix S.A. (Translation of registrant's name into English) 60 Rue de Wattignies 75012 Paris, France (Address of principal executive office) Ind |
|
| April 11, 2023 |
Voting Rights and Shares Capital of the Company EXHIBIT 99.1 Voting Rights and Shares Capital of the Company PARIS, April 11, 2023 (GLOBE NEWSWIRE) - In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, April 11, 2023 Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq |
